 Randomization Method: After the screening visit, subjects who meet the inclusion and exclusion criteria, will be assigned a number by a computerized random number generation program Microsoft office - Excel and randomized to receive subcutaneous injection daily of either Liraglutide 0.6mg 18 subjects, 1.2 mg 18 subjects, 1.8 mg 18 subjects or placebo 18 subjects for 12 weeks. The subjects and the study coordinators will be blinded to the treatment. The Liraglutideplacebo will be administered via a pen kit obtained from Novo Nordisk Pharmaceuticals. The dose will be given in the morning. The sponsor is providing study medication in blinded form. 